Navigation Links
Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer
Date:7/14/2014

CAMBRIDGE, Mass., July 14, 2014 /PRNewswire/ -- Minerva Neurosciences (NASDAQ: NERV), a leader in the development of new therapies to treat neuropsychiatric diseases and disorders, today announced that Frederick W. Ahlholm has been appointed vice president of finance and chief accounting officer, effective June 2, 2014. 

Mr. Ahlholm is a senior executive with more than 20 years of experience in directing the financial functions at technology and life science companies. His background includes the management of compliance and reporting requirements for companies registered with the U.S. Securities and Exchange Commission. Previously he was vice president of finance and chief accounting officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. He is a CPA and earned his BBA at the University of Notre Dame.

"I am excited to be joining Minerva Neurosciences at this pivotal time, and am looking forward to working with the rest of the executive team to advance our business strategy targeting a range of unmet needs and highly promising commercial opportunities in neuropsychiatric health in the years ahead," said Mr. Ahlholm.

The news of Mr. Ahlholm's appointment comes on the heels of the pricing of the company's initial public offering on June 30, 2014. Shares began trading on the NASDAQ Global Market under the ticker symbol "NERV" on July 1, 2014.

"Frederick's extensive experience with life sciences companies and his proven ability to contribute to the growth and success of clinical-stage organizations make him an ideal addition to the senior team at Minerva Neurosciences," said Rogerio Vivaldi, MD, MBA, Minerva president and CEO.

About Minerva
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. The company was incorporated under the name Cyrenaic Pharmaceuticals, Inc. on April 23, 2007. In November 2013, it merged with Sonkei Pharmaceuticals, Inc. and the combined company was renamed Minerva Neurosciences, Inc. 

Media contact:
Jen Ringler
Berry & Company Public Relations
212.253.8881
jringler@berrypr.com

Investor contact:
Renee Leck
Stern Investor Relations
212.362.1200
renee@sternir.com


'/>"/>
SOURCE Minerva Neurosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
2. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
3. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
4. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
5. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
6. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
7. Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells
8. Ceres Announces Fiscal Third Quarter 2014 Financial Results
9. Pittcon Announces Second Year Partnership With Food Safety Tech
10. Organovo Announces Collaboration with National Institutes of Health
11. iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK and the ... associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has just ... the full article now. , The studies analyzed for the new report included ...
(Date:5/27/2016)... , May 27, 2016 At present, ... playing in this space know that volatility is what makes ... companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ... Inc. (NASDAQ: LPTN ), and Heat Biologics Inc. ... access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):